Increased use of lipid-lowering therapy in patients receiving human immunodeficiency virus protease inhibitors.

This publication has 18 references indexed in Scilit:

• Protease inhibitors and cardiovascular outcomes in patients with HIV-1
  The Lancet, 2002
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
  Published by Elsevier ,2002
• Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
  The Lancet, 2001
• Use of Human Immunodeficiency Virus-1 Protease Inhibitors Is Associated With Atherogenic Lipoprotein Changes and Endothelial Dysfunction
  Circulation, 2001
• Premature atherosclerosis in HIV-infected individuals – focus on protease inhibitor therapy
  AIDS, 2001
• Preliminary Guidelines for the Evaluation and Management of Dyslipidemia in Adults Infected with Human Immunodeficiency Virus and Receiving Antiretroviral Therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group
  Clinical Infectious Diseases, 2000
• A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
  AIDS, 1998
• Severe premature coronary artery disease with protease inhibitors
  The Lancet, 1998
• HIV-Protease Inhibitors
  New England Journal of Medicine, 1998
• Ritonavir
  Clinical Pharmacokinetics, 1998